Milestone Asset Management LLC Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Milestone Asset Management LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 11.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,998 shares of the medical research company’s stock after buying an additional 204 shares during the quarter. Milestone Asset Management LLC’s holdings in IQVIA were worth $393,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter valued at $27,000. Park Place Capital Corp bought a new stake in IQVIA during the third quarter valued at about $28,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. raised its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. lifted its position in shares of IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after buying an additional 99 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Truist Financial decreased their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Finally, Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $201.42 on Friday. The firm has a fifty day simple moving average of $200.34 and a two-hundred day simple moving average of $220.78. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a market capitalization of $36.56 billion, a P/E ratio of 26.43, a PEG ratio of 2.14 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.